Market Overview - U.S. stock futures showed volatility with mixed performance after a significant sell-off on Thursday, with the S&P 500 index dropping below key support levels [1][2] - The S&P 500 index fell below its 50-day moving average for the first time in months, indicating potential bearish sentiment [1] Economic Indicators - September's job report revealed non-farm payrolls increased by 119,000, significantly exceeding the forecast of 50,000, which dampened expectations for interest rate cuts [2] - The 10-year Treasury bond yield was at 4.08%, while the two-year bond yield stood at 3.53%, reflecting market sentiment on interest rates [2] Futures Performance - Dow Jones futures increased by 0.28%, while S&P 500 and Nasdaq 100 futures decreased by 0.14% and 0.47%, respectively [3] - The SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ Trust ETF (QQQ) both experienced declines in premarket trading, with SPY down 0.35% and QQQ down 0.77% [3] Company Highlights - New Fortress Energy Inc. surged by 19.86% due to successful debt restructuring efforts [5] - Gap Inc. advanced by 3.86% after reporting strong third-quarter results and raising its FY25 sales guidance [5] - Veeva Systems Inc. saw a decline of 6.69% despite positive third-quarter results and raised fiscal year estimates [4][5] - Elastic NV dropped by 12.21% despite a solid earnings beat and strong guidance for the current quarter [5] - Intuit Inc. rose by 3.23% after reporting better-than-expected first-quarter results, although it expects second-quarter adjusted earnings to be below estimates [14] Analyst Insights - Scott Wren from Wells Fargo Investment Institute maintains a bullish outlook for the equity market through 2026, forecasting an accelerating economy driven by deregulation and expected Federal Reserve rate cuts [10][11] - Wren suggests reallocating investments from fully valued technology sectors into Financials and Industrials, which are expected to benefit from AI infrastructure growth [12]

Market Overview - U.S. stock futures showed volatility with mixed performance after a significant sell-off on Thursday, with the S&P 500 index dropping below the support line of 6,550 and its 50-day moving average for the first time in months [1][2] - The September job report revealed non-farm payrolls increased by 119,000, exceeding economists' expectations of 50,000, impacting market expectations for interest rate cuts [2] Futures Performance - Dow Jones futures increased by 0.28%, while S&P 500 and Nasdaq 100 futures decreased by 0.14% and 0.47%, respectively [3] - The SPDR S&P 500 ETF Trust (SPY) fell by 0.35% to $650.25, and the Invesco QQQ Trust ETF (QQQ) declined by 0.77% to $581.15 in premarket trading [3] Stocks in Focus - New Fortress Energy Inc. surged by 19.86% due to debt restructuring efforts, while Gap Inc. rose by 3.86% after positive third-quarter results and an increase in FY25 sales guidance [4][5] - Veeva Systems Inc. dropped by 6.69% despite strong quarterly results and raised fiscal year estimates, while Elastic NV fell by 12.21% despite a solid earnings beat and strong guidance [4][5] Analyst Insights - Scott Wren from Wells Fargo Investment Institute maintains a bullish outlook for the equity market through 2026, forecasting an accelerating economy driven by deregulation and expected Federal Reserve rate cuts [10][11] - Wren advises reallocating investments from fully valued technology sectors into Financials and Industrials, which are expected to benefit from AI infrastructure growth [12] Upcoming Economic Data - Investors are anticipating key economic data releases, including November's S&P flash U.S. services and manufacturing PMI and final consumer sentiment data [15]

Core Insights - Veeva Systems reported a revenue of $811.24 million for the quarter ended October 2025, reflecting a 16% increase year-over-year and surpassing the Zacks Consensus Estimate of $791.88 million by 2.44% [1] - The company's EPS for the quarter was $2.04, up from $1.75 in the same quarter last year, exceeding the consensus EPS estimate of $1.95 by 4.62% [1] Revenue Breakdown - Subscription services revenue reached $682.5 million, exceeding the average estimate of $671.02 million, with a year-over-year growth of 17.5% [4] - Professional services and other revenue totaled $128.74 million, surpassing the average estimate of $120.86 million, marking an 8.8% increase year-over-year [4] - Veeva R&D Solutions generated $81.28 million in revenue, exceeding the average estimate of $74.66 million, representing a 12.1% year-over-year increase [4] - Subscription services from Veeva R&D Solutions amounted to $364.85 million, above the average estimate of $361.28 million, with a year-over-year growth of 20.6% [4] - Veeva Commercial Solutions' subscription services revenue was $317.65 million, exceeding the average estimate of $309.72 million, reflecting a 14.1% increase year-over-year [4] - Professional services and other revenue from Veeva Commercial Solutions reached $47.46 million, surpassing the average estimate of $46.26 million, with a year-over-year change of 3.5% [4] Margin Analysis - Non-GAAP Gross Margin for Professional services and other was reported at 29.8%, below the average estimate of 31.8% [4] - Non-GAAP Gross Margin for Subscription services was 86.6%, slightly above the average estimate of 85.9% [4] Stock Performance - Veeva's shares have returned -5.8% over the past month, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Veeva Systems reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.95 per share, and up from $1.75 per share a year ago [1][2] - The company achieved revenues of $811.24 million for the quarter, surpassing the Zacks Consensus Estimate by 2.44% and increasing from $699.21 million year-over-year [3] - Veeva has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2][3] Earnings Performance - The earnings surprise for the recent quarter was +4.62%, following a previous surprise of +4.74% [2] - The current consensus EPS estimate for the upcoming quarter is $1.87, with expected revenues of $798.22 million, while the estimate for the current fiscal year is $7.78 on $3.14 billion in revenues [8] Stock Performance - Veeva shares have increased approximately 29.8% since the beginning of the year, compared to a 12.9% gain for the S&P 500 [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Outlook - The Medical Info Systems industry, to which Veeva belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [6] - CRM now constitutes about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [9] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative, with significant progress expected to benefit customers and the industry [6] - Crossix continues to perform well, with expectations for it to remain a growth driver in the coming years [34][39] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong, with no significant changes in customer buying behaviors noted [31] - Digital marketing spending is increasing, which positively impacts Crossix's business [39] Company Strategy and Development Direction - The company is focused on delivering integrated solutions across clinical operations and clinical data to drive efficiency [11] - Veeva aims to leverage its consulting, data, and software capabilities to provide comprehensive solutions for life sciences [47][48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the industry, citing ongoing demand for innovative solutions to address uncured diseases [31] - The company anticipates no material impact on its 2030 goals despite some customer attrition in the CRM segment [9][75] Other Important Information - The company is investing in product and services teams, which may impact margins in the short term but is expected to yield positive results over time [58] - The partnership with IQVIA is seen as beneficial, enhancing customer confidence and operational capabilities [41][42] Q&A Session Summary Question: Concerns about CRM customer migration - Management acknowledged that CRM is about 20% of total revenue and that attrition is expected to have no immediate impact on 2030 goals [9][75] Question: Competitive landscape in EDC market - Management noted that while one customer returned to a previous provider, overall trends in clinical remain positive with opportunities for growth [11] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry is cautious about making significant changes [28] Question: Demand environment in pharma - Management reported that the industry is healthy, with no significant changes in customer buying behaviors despite external political factors [31] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver moving forward [34][39] Question: Quality cloud expansion - Management highlighted that the quality cloud opportunity is expanding through reaching new customer types and product expansion [80]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [6] - CRM now constitutes about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [9] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative with significant progress, expected to add value across various product areas including Vault CRM, Crossix, clinical, and safety [6] - Crossix continues to perform well, with expectations for it to remain a growth driver in the coming years [34] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong despite political chaos, with no significant changes in customer buying behaviors noted [31] - Digital marketing spending is increasing, which benefits Crossix as it becomes a standard for measurement and optimization [39] Company Strategy and Development Direction - The company is focused on delivering integrated solutions across clinical operations and clinical data, emphasizing efficiency as a key driver [11] - Veeva aims to be a comprehensive provider in the life sciences sector, integrating software, data, and consulting services [47] Management's Comments on Operating Environment and Future Outlook - Management expresses optimism about the industry, citing ongoing demand for innovative solutions to address uncured diseases [31] - The company anticipates no material impact on its 2030 goals despite some customer attrition in the CRM segment, as the business is diverse and has multiple growth paths [75][76] Other Important Information - The company is investing in product and services teams, with a focus on business consulting and professional services to enhance customer engagement [59] - The partnership with IQVIA is seen as a positive trend, enhancing customer confidence and operational capabilities [42] Q&A Session Summary Question: Concerns about CRM customer migration - Management noted that CRM is currently about 20% of total revenue, down from 25% two years ago, and emphasized that no immediate impact is expected from customer migrations [9][19] Question: Competitive landscape in EDC market - Management acknowledged a competitor winning back a top 20 customer but expressed confidence in their own pipeline and opportunities in the EDC market [10][11] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry remains cautious about significant changes due to the need for relationship building [28] Question: Demand environment and financial health of pharma market - Management reported that the pharmaceutical industry is healthy, with no significant changes in demand or buying behavior observed [31] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver in the future [34][70] Question: Insights from customer-specific factors affecting CRM wins - Management stated that customer-specific dynamics are at play, with no overarching pattern, and emphasized the health of the overall CRM business [56][57]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [5] - CRM revenue has decreased to about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [8] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative, with significant progress expected to benefit customers and the industry [5] - Crossix continues to perform well, contributing to overall revenue growth, with expectations for it to remain a strong growth driver [32][37] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong, with no significant changes in customer buying behaviors noted [28] - Digital marketing spending is increasing, which positively impacts Crossix's performance and growth potential [36] Company Strategy and Development Direction - The company is focused on integrating its software, data, and consulting services to provide comprehensive solutions for life sciences [44] - There is an emphasis on innovation in clinical and safety areas, with expectations for AI to drive efficiency and effectiveness [19][48] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the industry, citing ongoing demand for solutions to uncured diseases and a stable market environment [28] - The company expects to continue to meet its 2030 goals despite some customer attrition in the CRM segment, due to the diverse nature of its business [73] Other Important Information - The company is investing in hiring for product and services teams to support growth and innovation [55] - The partnership with IQVIA is seen as beneficial, enhancing customer confidence and providing opportunities for joint solutions [40] Q&A Session Summary Question: Concerns about CRM customer migration - Management acknowledged that CRM is currently about 20% of total revenue and that attrition is not expected to impact long-term goals [8][73] Question: Competitive landscape in EDC market - Management noted that while one customer returned to a previous provider, overall trends in clinical operations remain positive, with opportunities for growth [10] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry is cautious about making significant changes [26] Question: Demand environment in pharma - Management reported that the industry is healthy, with no significant changes in customer buying behaviors despite political and economic challenges [28] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver moving forward [32][37] Question: Balancing go-to-market initiatives - Management stated that dedicated teams are in place to focus on various product areas, allowing for simultaneous advancement in multiple initiatives [68]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Q3'26 Quarterly Results November 20, 2025 This presentation and associated commentary contain forward-looking statements regarding Veeva's expected future performance and, in particular, includes guidance, provided as of November 20, 2025, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that ac ...

Core Insights - Veeva Systems Inc. reported total revenues of $811.2 million for the third quarter of fiscal 2026, representing a 16% increase year over year. Subscription services revenues were $682.5 million, up 17% year over year [1][9] - The company is on track to achieve its 2030 revenue run-rate goal of $6 billion, with strong performance across its business segments [2][9] - Veeva AI is advancing rapidly, with early adopter projects showing significant value in specialized AI applications for the life sciences industry [2] Financial Performance - Total revenues for the third quarter were $811.2 million, up from $699.2 million a year ago, marking a 16% increase [9] - Subscription services revenues increased to $682.5 million from $580.9 million, a 17% year-over-year growth [9] - Operating income for the third quarter was $240.9 million, a 33% increase from $181.4 million year over year [9] - Non-GAAP operating income was $364.9 million, up 20% from $304.0 million year over year [9] - Net income for the third quarter was $236.2 million, a 27% increase from $185.8 million year over year [9] - Non-GAAP net income was $345.1 million, up 20% from $288.3 million year over year [9] - Fully diluted net income per share was $1.40, compared to $1.13 a year ago, while non-GAAP fully diluted net income per share was $2.04, up from $1.75 [9] Strategic Developments - Veeva AI is set to release its first specialized AI agents for CRM and commercial content in early December, with additional agents planned for 2026 [9] - The company added 23 new customers to its Vault CRM platform, bringing the total to 115 customers live, including a significant rollout in Japan for a top 20 biopharma [9] - Veeva Development Cloud has been selected as the enterprise standard by three top 20 biopharmas, indicating strong demand for its applications [9] Guidance and Outlook - Veeva provided guidance for its fiscal fourth quarter ending January 31, 2026, expecting total revenues between $807 million and $810 million [3] - For the full fiscal year ending January 31, 2026, Veeva expects total revenues between $3,166 million and $3,169 million [3]